{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Martin AL"],"funding":["NCI NIH HHS"],"pagination":["2236-2242"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10241930"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["128(12)"],"pubmed_abstract":["<h4>Background</h4>The study objective is to examine the impact of obesity on frontline carboplatin dosing in the neoadjuvant and adjuvant settings and to evaluate the association of dosing with survival among epithelial ovarian cancer (EOC) patients.<h4>Methods</h4>We selected 1527 women diagnosed with EOC from January 1, 2011 to October 20, 2021 from a nationwide electronic health record-derived de-identified database. The dose reduction of frontline carboplatin was defined as a relative dose intensity (RDI) < 0.85. Cox proportional hazards regression was used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association of RDI with survival overall and by histology.<h4>Results</h4>Women with a BMI ≥ 30 kg/m<sup>2</sup> versus <30 kg/m<sup>2</sup> were more likely "],"journal":["British journal of cancer"],"pubmed_title":["Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer."],"pmcid":["PMC10241930"],"funding_grant_id":["P30 CA076292"],"pubmed_authors":["Peres LC","Martin AL","Chern JY","Sinha SK","Colin-Leitzinger CM"],"additional_accession":[]},"is_claimable":false,"name":"Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer.","description":"<h4>Background</h4>The study objective is to examine the impact of obesity on frontline carboplatin dosing in the neoadjuvant and adjuvant settings and to evaluate the association of dosing with survival among epithelial ovarian cancer (EOC) patients.<h4>Methods</h4>We selected 1527 women diagnosed with EOC from January 1, 2011 to October 20, 2021 from a nationwide electronic health record-derived de-identified database. The dose reduction of frontline carboplatin was defined as a relative dose intensity (RDI) < 0.85. Cox proportional hazards regression was used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association of RDI with survival overall and by histology.<h4>Results</h4>Women with a BMI ≥ 30 kg/m<sup>2</sup> versus <30 kg/m<sup>2</sup> were more likely ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2025-04-18T20:12:47.346Z","creation":"2025-04-07T08:06:09.079Z"},"accession":"S-EPMC10241930","cross_references":{"pubmed":["37024666"],"doi":["10.1038/s41416-023-02259-1"]}}